A big STEP for treatment of heart failure with preserved ejection fraction

Subodh Verma; Barry A Borlaug; Javed Butler; Melanie J Davies; Dalane W Kitzman; Mark C Petrie; Sanjiv J Shah; Nitish K Dhingra; Mikhail N Kosiborod

doi:10.1016/j.cmet.2023.08.003

A big STEP for treatment of heart failure with preserved ejection fraction

Cell Metab. 2023 Oct 3;35(10):1681-1687. doi: 10.1016/j.cmet.2023.08.003. Epub 2023 Aug 28.

Authors

Subodh Verma¹, Barry A Borlaug², Javed Butler³, Melanie J Davies⁴, Dalane W Kitzman⁵, Mark C Petrie⁶, Sanjiv J Shah⁷, Nitish K Dhingra⁸, Mikhail N Kosiborod⁹

Affiliations

¹ Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, Toronto, ON, Canada; Department of Surgery, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. Electronic address: subodh.verma@unityhealth.to.
² Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
³ Baylor Scott and White Research Institute, Dallas, TX, USA; Department of Medicine, University of Mississippi, Jackson, MS, USA.
⁴ Leicester Diabetes Research Centre, University of Leicester, Leicester, UK; Leicester National Institute for Health Research Biomedical Research Centre, University Hospitals of Leicester NHS Trust, Leicester, UK.
⁵ Department of Internal Medicine, Sections of Cardiovascular Medicine and Geriatrics and Gerontology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
⁶ Institute of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
⁷ Division of Cardiology, Department of Medicine, and Bluhm Cardiovascular Institute, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
⁸ Division of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, Toronto, ON, Canada.
⁹ Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA. Electronic address: mkosiborod@saint-lukes.org.

PMID: 37643614
DOI: 10.1016/j.cmet.2023.08.003

Abstract

In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.